Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 102 results for cisplatin

  1. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development Reference number: GID-TA11023 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)

    Evidence-based recommendations on cetuximab (Erbitux) for treating locally advanced squamous cell cancer of the head and neck in adults.

    Technology appraisal guidance
    Published
    25 June 2008
    View recommendations

    Sections for TA145

  3. Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)

    Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    29 June 2011
    View recommendations

    Sections for TA227

  4. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA817

  5. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.

    Technology appraisal guidance
    Last updated
    29 August 2024
    View recommendations

    Sections for TA737

  6. Capecitabine for the treatment of advanced gastric cancer (TA191)

    Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.

    Technology appraisal guidance
    Published
    28 July 2010
    View recommendations

    Sections for TA191

  7. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)

    Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.

    Technology appraisal guidance
    Published
    10 March 2021
    View recommendations

    Sections for TA683

  8. Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

    Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA643

  9. Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

    In development Reference number: GID-TA11504 Expected publication date:  28 January 2026

    Technology appraisal guidance
    In development

  10. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1060)

    Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    8 May 2025

    Sections for TA1060

  11. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

    Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    18 July 2018

    Sections for TA531

  12. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development Reference number: GID-TA11137 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Awaiting development Reference number: GID-TA11338 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

    Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.

    Technology appraisal guidance
    Published
    13 June 2018
    View recommendations

    Sections for TA525

  15. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6607]

    In development Reference number: GID-TA11694 Expected publication date: TBC

    Technology appraisal guidance
    In development